Key Segments
By Product
-
Naltrexone
-
Buprenorphine
-
BELBUCA
-
Sublocade
-
Suboxone
-
Zubsolv
-
Others
-
By Route of Administration
-
Naltrexone
-
Oral Administration
-
Injectable Administration
-
Implantable Administration
-
-
Buprenorphine
-
Oral Administration
-
Injectable Administration
-
Implantable Administration
-
By Application
-
Naltrexone
-
Opioid use disorder (OUD)
-
Alcohol use disorder (AUD)
-
-
Buprenorphine
-
Opioid use disorder (OUD)
-
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Naltrexone and Buprenorphine market.
One significant barrier is MAT (medication-assisted treatment) related stigma, which restricts reach, even among individuals who have been diagnosed.
Growing access to naltrexone and buprenorphine globally, heightened government support, and advancements in drug delivery devices are factors driving the naltrexone and buprenorphine market.
The market is expected to reach USD 8.54 billion by 2032, increasing from USD 4.20 billion in 2024.
The Naltrexone and Buprenorphine market is anticipated to grow at a CAGR of 9.30% from 2025 to 2032.